Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in metabolic dysfunction-associated steatohepatitis, WHIM syndrome and pediatric ...
Smith covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, MoonLake Immunotherapeutics, and Madrigal Pharmaceuticals. Viking Therapeutics has an analyst ...
Look no further than our top two stories of the year, and you’ll see that the GLP-1 craze and Big Pharma layoffs took center ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ultragenyx Pharmaceutical (RARE – Research ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Infinity Pharmaceuticals Inc.-90.00% $907.61 ...
Goldman Sachs’ Asad Haider likes the prospects for medical technology companies, mid-cap biotechs, drug distributors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback